


COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0032

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number 10/187,215 10/649,378
 Filing Date June 27, 2002 August 26, 2003
 First Named Inventor Alan M. Fogelman
 Group Art Unit 1614
 Examiner Name Unassigned
 Attorney Docket Number 407T-911220US 407T-911270US
 Date Submitted February 5, 2003 Nov. 11, 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
<i>JR</i>	01	3,767,040		Tushaus	10-23-1973	428/352
<i>JR</i>	02	4,155,913		Hellerbach et al.	05-22-1979	540/560
<i>JR</i>	03	4,643,988		Segrest et al.	02-17-1987	514/12
<i>JR</i>	04	5,721,138		Lawn	02-24-1998	435/325
<i>JR</i>	05	5,733,549		Yamada et al.	03-31-1998	424/185.1
<i>JR</i>	06	5,814,467		Curtiss et al.	09-29-1998	435/7.9
<i>JR</i>	07	5,854,238		Kempen	12-29-1998	514/220
<i>JR</i>	08	6,037,323		Dasseux et al.	03-14-2000	514/12
<i>JR</i>	09	6,086,918		Stern et al.	07-11-2000	424/474

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
<i>JR</i>	10	WO	97/36927	A1	Boffelli et al.	10-09-1997		
<i>JR</i>	11	WO	99/47566	A1	The UAB Research Foundation	09-23-1999		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
<i>JR</i>	12	ANANTHARAMAIAH (1986) "Synthetic Peptide Analogs of Apolipoproteins." <i>Methods in Enzymology</i> 128:627-647	
<i>JR</i>	13	ANANTHARAMAIAH and GARBER (1996) "Chromatographic Methods for Quantitation of Apolipoprotein A-I." <i>Meth. Enzymol.</i> 263: 267-282	
<i>JR</i>	14	ANANTHARAMAIAH et al. (1985) "Studies of Synthetic Peptide of the Amphipathic Helix." <i>The Journal of Biological Chemistry</i> 260:10248-10255	
<i>JR</i>	15	ANANTHARAMAIAH et al. (1990) "Use of Synthetic Peptide Analogues to Localize Lecithin: Cholesterol Acyltransferase Activating Domain in Apolipoprotein A-I." <i>Arteriosclerosis</i> 10:95-105	

Examiner Signature	<u>Jeffrey E. Russell</u>	Date Considered	<u>April 17, 2005</u>
--------------------	---------------------------	-----------------	-----------------------

*EXAMINER: Initial if relevant, not considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/107,213 10/104,378
Filing Date	June 27, 2002 August 26, 2003
First Named Inventor	Alan M. Fogelman
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	4077-011220US 4081-911270US
Date Submitted	February 5, 2003 11/11/03




16	ANANTHARAMAIAH et al. (1993) "An Atlas of the Amphipathic Helical Domains of Human Exchangeable Plasma Apolipoproteins." Chapter. 6:109-142 In: <i>The Amphipathic Helix</i> (Epanand, R. M., ed), CRC Press, Boca Raton, FL
17	ARMSTRONG et al. (1993) D amino acid levels in human physiological fluids, <i>Chirality</i> , 5: 375-378
18	BADIMON et al. (1990) "Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-fed Rabbit." <i>J. Clinical Investigation</i> 85:1234-1241
19	BAUER et al. (1982) "SMS 201-995: A Very Potent and Selective Octapeptide Analogue of Somatostatin with Prolonged Action" <i>Life Sciences</i> 31:1133-1140.
20	BOFFELLI et al. (1997) "Reconstitution and Further Characterization of the Cholesterol Transport Activity of the Small-Intestinal Brush Border Membrane" <i>Biochemistry</i> 36:10784-10792.
21	BOFFELLI et al. (1997) "The uptake of cholesterol at the small-intestinal brush border membrane is inhibited by apolipoproteins." <i>FEBS Letters</i> , 411: 7-11
22	BORHANI et al. (1999) "Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation." <i>Proc. Natl. Acad. Sci. USA.</i> 94:12291-12296
23	BROUILLETTE and ANANTHARAMAIAH (1995) "Structural models of human apolipoprotein A-I." <i>Biochim. Biophys. Acta</i> 1256: 103-129
24	BROUILLETTE et al. (2001) "Structural Models of Human Apolipoprotein A-I: A Critical Analysis and Review" <i>Biochimica et Biophysica Acta</i> 55753:1-44.
25	Canadian Pharmacists Association, Starlix General Monograph. http://cpha.infinetcomm.com/content/hcp/tools/cps_cnp_updates/starlix.cfm (2002)
26	CHUNG et al. (1985) "Studies of Synthetic Peptide Analogs of the Amphipathic Helix." <i>J. Biol. Chem.</i> 60(18): 10256-10262
27	DATTA et al. (2001) "Effects of Increasing Hydrophobicity on the Physical-Chemical and Biological Properties of a Class A Amphipathic Helical Peptide. <i>J Lipid Research</i> 42:1096-1104.
28	DAVIDSON et al. (1994) "The Influence of Apolipoprotein Structure on the Efflux of Cellular Free Cholesterol to High Density Lipoprotein." <i>J. Biol. Chem.</i> 269(37): 22975-22982
29	DIEDERICH et al. (2001) "Apolipoprotein AI and HDL ₃ Inhibit Spreading of Primary Human Monocytes through a Mechanism that Involves Cholesterol Depletion and Regulation of CD42." <i>Atherosclerosis</i> 159:313-324.
30	DOOLEY et al. (1994) "An All D-Amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library" <i>Science</i> 2019-2022.

Examiner Signature	Jeffrey E. Russe	Date Considered	April 14, 2005
--------------------	------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, with or without citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/187,215 10/649,378
	Filing Date	June 27, 2002 August 25, 2003
	First Named Inventor	Alan M. Fog Iman
	Group Art Unit	1614
	Examiner Name	Unassigned
	Attorney Docket Number	407T-011220US: 407T-911270US
Date Submitted	November 11, 2003	



31	DUNLOP and NEIDLE (1997) "The Orgion and Turnover of D-Serine in Brain." <i>Biochemical and Biophysical Research Communication</i> 235:26-30
32	EHARA et al. (2001) "Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes." <i>Circulation</i> 103:1955-1960
33	EPAND et al. (1987) "Studies Synthetic Peptide Analog of the Amphipathic Helix" <i>J. Biol. Chem.</i> 262(19): 9389-9396
34	FIELD et al. (2001) "Gene expression of sterol regulatory element-binding proteins in hamster small intestine." <i>Journal of Lipid Research</i> 42:1-9
35	FIELDING and FIELDING (1995) "Molecular physiology of reverse cholesterol transport." <i>J. Lipid Res.</i> 36: 211-228
36	FIELDING et al. (1972) "A Protein of Lecithin: Cholester Acyltransferase." <i>Biochem. Biophys. Res. Comm.</i> 46(2):1493-1498
37	FRICKER et al. (1995) "Enteral Absorption of Octreotide: Modulation of Intestinal Permeability by Distinct Carbohydrates" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 274:826-832
38	FUESSL et al. (1987) "Oral Absorption of the Somatostatin Analogue SMS 201-995: Theoretical and Practical Implications" <i>Clinical Science</i> 72: 255-257.
39	GARBER et al. (1992) "Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties." <i>Arteriosclerosis and Thrombosis</i> , 12(8): 886-894
40	GARBER et al. (1997) <i>Circulation</i> 96:1-490
41	GARBER et al. (1999) "Protection against Atherosclerosis in Mice by a Synthetic Class A Amphipathic Peptide Analog of Apolipoprotein A-I." <i>Circulation</i> 100: 2838
42	GARBER et al. (2001) "A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis." <i>Journal of Lipid Research</i> 42:-545-552
43	GLOMSET (1968) "The Plasma lecithin: cholesterol acyltransferase reaction." <i>J. Lipid Res.</i> 9:155-167
44	GONG et al. (1994) "Structural and functional properties of human and mouse apolipoprotein A-I." <i>Biochim. Biophys. Acta</i> 1213:335-342
45	GURFINKEL et al. (2002) "Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions. The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study" <i>Circulation</i> 105:2143-2147.
46	HAMASE et al. (2001) "Determination of Free D-Proline and D-Leucine in the Brains of Mutant Mice Lacking D-Amino Acid Oxidase Activity" <i>Analytical Biochemistry</i> 298:253-258.

Examiner Signature	Jeffrey E. Russel	Date Considered	April 14, 2005
--------------------	-------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/107,215 10/164,378
Filing Date	June 27, 2002 August 26, 2003
First Named Inventor	Alan M. F. gelman
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	4077-911220US 4077-911270US
Date Submitted	February 5, 2003 11/11/03

47	HARDY et al. (2001) "An Automated High-Performance Liquid Chromatography Procedure for the Quantitation of L- and D-Amino Acids by Means of Stepwise Precolumn Derivatization" <i>Analytical Biochemistry</i> 291:297-299.
48	HASHIMOTO et al. (2000) "Improvement of intestinal absorption of peptides: absorption of B1-Phe monoglucosylated insulin to rat intestinal brush-border membrane vesicles." <i>J. Pharmaceutics & Therapeutics</i> 50(2):197-204
49	HAUSER et al. (1998) "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine" <i>Biochemistry</i> 178423-17850.
50	HAYRY et al. "Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat." <i>FASEB J.</i> 9(13):1336-1344 (1995)
51	HYKA et al. (2001) "Apolipoprotein A-I Inhibits the Production of Interleukin-1beta and Tumor Necrosis Factor-alpha by Blocking Contact-Mediated Activation of Monocytes by T Lymphocytes." <i>Blood</i> 97:2381-2389.
52	JOHNSON et al. (1991) "Cholesterol transport between cells and high-density lipoproteins." <i>Biochim. Biophys. Acta.</i> 1085: 273-298
53	JONAS (1991) "Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins." <i>Biochim. Biophys. Acta</i> 1084: 205-220
54	JONAS (2000) Lecithin cholesterol acyltransferase." <i>Biochim. Biophys. Acta</i> 1529: 245-256
55	JONES et al. (1992) "Computer Programs to Identify and Classify Amphipathic alpha Helical Domains" <i>Journal of Lipid Research</i> 33:287-296.
56	KIGASAWA et al. (1995) "Inhibition of corneal ulceration by tetrapeptidyl hydroxamic acid." <i>Jap. J. Ophthalmology</i> 39(1):35-42
57	KREIGER (1999) "Charting The Fate of the "Good Cholesterol": Identification and Characterization of the High-Density Lipoprotein Receptor Sr-Bi." <i>Ann Rev. Biochem.</i> 68: 523-558
58	KULLMAN et al. (1999) "Evaluation of the Enantiomeric Composition of Amino Acids in Tobacco" <i>Chirality</i> 11:669-673.
59	SENIOR (1999) "New options developed for needle-free drug delivery" <i>Lancet</i> Sept. 25, 1999
60	LEVI et al. (2000) "A retro-inverso miniantibody with anti-HIV activity." <i>Aids Res. & Human Retrovirus</i> 16(1):59-65.
61	LUNDIN et al. (1986) "Absorption of Intragastrically Administered DDAVP in Conscious Dogs" <i>Life Sciences</i> 38:703-709.
62	MAN et al. (1987) D-aspartate in human brain." <i>J Neurochem</i> 48:510-515

Examiner
Signature

Jeffrey E. Russell

Date
Considered

April 14, 2005

*EXAMINER: Initial if r f r nc considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/107,215 10/649,378
Filing Date	June 27, 2002 August 26, 2003
First Named Inventor	Alan M. Fogelman
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	4077-91122003 4077-911270 US
Date Submitted	February 5, 2003 4/11/03



63	MERRIFIELD et al. (1995) "Retro and Retroenantio Analogs of Cecropin-Melittin Hybrids" <i>Proc Natl Acad Sci USA</i> 92: 3449-3453.
64	MISHRA et al. (1994) "Interaction of Synthetic Peptide Analogs of the Class A" <i>J. Biol. Chem.</i> 269: 7185-7191
65	MISHRA et al. (1995) "Effect of the Arrangement of Tandem Repeating Units of Class A Amphipathic alpha-Helices on Lipid Interaction." <i>J. Biol. Chem.</i> 270: 1602-1611
66	MISHRA et al. (1998) "Studies of Synthetic Peptides of Human Apolipoprotein A-I Containing Tandem Amphipathic alpha-Helices" <i>Biochemistry</i> 37: 10313-10324
67	MOR et al. (1992) Enter a new post-translational modification: D-amino acids in gene-encoded peptides, <i>TIBS</i> , 17: 481-485
68	NAGATA et al. (1994) "Distribution of free D-serine in vertebrate brains", <i>Brain Res.</i> , 634: 291-295.
69	NAGATA et al. (1995) "Free D-serine concentration in normal and Alzheimer human brain", <i>Brain Res. Bull.</i> , 38(2): 181-183
70	NAVAB et al. (2000) "Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1." <i>J. Lipid Res.</i> 41: 1481-1494
71	NAVAB et al. (2000) "Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3." <i>J. Lipid Res.</i> 41: 1495-1508
72	NAVAB et al. (2002) "Oral Administration of an Apo A-I Mimetic Peptide Synthesized from D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol" <i>Circulation</i> 105: 290-292.
73	NOMOTO et al. (1998) "Improved of intestinal absorbtion of peptide drugs by Gyycosylation: Transport of Tetrapeptide by the Sodium Ion-Dependent D-Glucose Transporter." <i>J. Pharmaceutics Science</i> 87(3):326-332.
74	OHTANI et al. (1995) Age-related changes in D-aspartic acid of rat teeth, <i>Growth Develop. & Aging</i> , 59: 55-61
75	ORAM and YOKOYAMA (1996) "Apolipoprotein-mediated removal of cellular cholesterol and phospholipids." <i>J. Lipid Res.</i> 37: 2473-2491
76	OWENS et al. (1990) "Apolipoprotein A-I and its Amphipathic Helix Peptide Analogues Inhibit Human Immunodeficiency Virus-Induced Syncytium Formation" <i>J Clin Invest</i> 86: 1142-1150.
77	PAIGEN et al. (1990) "Atherosclerosis Susceptibility Differences among Progenitors of Recombinant Inbred Strains of Mice." <i>Arteriosclerosis</i> 10: 316-323
78	PALGUNACHARI et al. (1996) "Only the Two End Xelises of Eight Tandem Amphipathic Helical Domaine of Human Apo A-I Have Significant Lipid Affinity." <i>Arteriosclerosis, Thrombosis, & Vascular Biology</i> 16: 328-338

Examiner Signature	Jeffrey E. Russel	Date Considered	April 18, 2005
--------------------	-------------------	-----------------	----------------

*EXAMINER: Initial if reference consid red, wheth r or not citation is in conformanc with MPEP 609. Draw line through citation if not in conformance and not considered. Includ copy of this form with next communication to applicant.


Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known

Application Number	10/407,215 10/649,378
Filing Date	June 27, 2002 August 26, 2003
First Named Inventor	Alan M. F gelman
Group Art Unit	1614
Examiner Name	Unassign d
Attorney Docket Number	407T-911220US 407T-911270US
Date Submitted	February 5, 2005 4/11/03

(use as many sheets as necessary)



79	PANIZZUTTI et al. (2001) "A New Strategy to Decrease N-methyl-D-aspartate (NMDA) Receptor Coactivation: Inhibition of D-serine Synthesis by Converting Serine Racemase into an Eliminase" <i>PNAS</i> 98:5294-5299.	
80	PAPPENHEIMER et al. (1994) "Intestinal Absorption and Excretion of Octapeptides Composed of D Amino Acids" <i>Proc Natl Acad Sci USA</i> 91: 1942-1945.	
81	PAPPENHEIMER et al. (1997) "Absorption and Excretion of Undegradable Peptides: Roles of Lipid Solubility and Net Charge." <i>J. Pharmacology & Experimental Therapeutics</i> 280(1):292-300	
82	PATSZTY et al. (1994) "Apolipoprotein AI Transgene Corrects Apolipoprotein E Deficiency-induced Atherosclerosis in Mice." <i>J. Clinical Investigation</i> 94:899-903	
83	PENG et al. (2001) "Effects of L-glutamate, D-aspartate, and Monensin on Glycolytic and Oxidative Glucose Metabolism in Mouse Astrocyte Cultures: Further Evidence that Glutamate Uptake is Metabolically Driven by Oxidative Metabolism" <i>Neurochemistry International</i> 38:437-443.	
84	PHARMALICENSING (27 Jan. 2001) Esperion Builds a Novel Peptides Program (2 pages)	
85	PHARMALICENSING (28 Jan. 2001) Multiple Peptide Systems Forms Joint Venture With Elan	
86	PHARMALICENSING (28 Jan. 2001) Unigene to Receive Patent for Delivery of Peptide Pharmaceuticals (2 pages)	
87	PHILIPS et al. (1993) "Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events." <i>Circulation</i> 88: 2762-2770	
88	PILONE (2000) D-amino acid oxidase: new findings. <i>CMLS, Cell. Mol. Life Sci.</i> , 57: 1732-1747	
89	PLUMP et al. (1994) "Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses stherosclerosis in the apolipoprotein E-deficient mouse." <i>Proc. Natl. Acad. Sci. USA</i> 91:9607-9611	
90	PURDUE NEWS (October 2000) 'Microspheres' Offer Promise for Oral Drug Delivery (3 pages)	
91	PURDUE NEWS (September 12, 1997) New Oral Insulin Delivery System Shows Promise (3 pages)	
92	REUBSAET et al. (1999) "Qualitative and quantitative aspects of the degradation of several tripeptides derived from the antitumour peptide antagonist [Arg ⁶ , D-Trp ^{7,9} , MePhe ⁸] substance P(6-11)." <i>J. Pharmaceut. & Biomed Analysis</i> 19(3-4):277-284	
93	RUBIN et al. (1991) "Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI." <i>Nature</i> 353:265-267	


Examiner Signature	Jeffrey E. Russel	Date Considered	April 14, 2005
--------------------	-------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PATENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/187,215 10/649,378
	Filing Date	June 27, 2002 August 26, 2003
	First Named Inventor	Alan M. F g Iman
	Group Art Unit	1614
	Examiner Name	Unassigned
	Attorney Docket Number	407T-9112200S: 407T-911270US
Date Submitted	February 5, 2003 4/11/03	



94	SEGREST et al. (1974) "A Molecular Theory of Lipid-Protein Interaction in the Plasma Lipoproteins." <i>FEBS Lett.</i> 38: 247-253	
95	SEGREST et al. (1990) "Amphipathic Helix Motif: Classes and Properties." <i>Proteins: Structure, Function and Genetics</i> 8: 103-117	
96	SEGREST et al. (1992) "The Amphipathic Helix in the Exchangeable Apolipoproteins: A Review of Secondary Structure and Function" <i>J Lipid Research</i> 33:141-166.	
97	SEGREST et al. (1994) "The Amphipathic alpha Helix: A Multifunctional Structural Motif in Plasma Apolipoproteins." <i>Adv. Prot. Chem.</i> 45: 303-369	
98	SEGREST et al. (2000) "Structure and function of apolipoprotein A-I and high-density lipoprotein." <i>Current Opin. Lipidol.</i> 11:105-115	
99	SHAH et al. (1998) "Effect of Recombinant Apolipoprotein A-I ^{Milano} on Aortic Atherosclerosis in Apolipoprotein E-Deficient Mice." <i>Circulation</i> 97:780-785.	
100	SINGH et al. (2000) "Innate Defences Against Viraemia" <i>Rev Med Virol</i> 10:395-403.	
101	SPRECHER et al. (1993) "The Low HDL Cholesterol/ High Triglyceride Trait." <i>Arterioscler. Thromb.</i> 13: 495-504	
102	SRINIVAS et al. (1990) "Antiviral Effects of Apolipoprotein A-I and Its Synthetic Amphipathic Peptide Analogs" <i>Virology</i> 176:48-57.	
103	Starlix MC—Amino Acid Fact Sheet. http://www.starlix.com/media_center/content/pages/amino.htm . (2002)	
104	SU AND AMIDON (1995) Investigation into the intestinal metabolism of [D-Ala] peptide T amide: implication for oral drug delivery, <i>Biochim et Biophys.</i> , 1245: 62-68	
105	THE WALL STREET JOURNAL (Jan 13, 2000) "Emisphere technologies develops oral Heparin"	
106	TSAL et al. (1998) D-serine added to antipsychotics for the treatment of schizophrenia. <i>Biol. Psychiatry</i> , 44: 1081-1089	
107	TAO et al. (2001) "Hibernation-induction Peptide and Cell Death: [D-Ala ² , D-Leu ⁵]enkephalin Blocks Bax-related Apoptotic Processes" <i>European Journal of Pharmacology</i> 428:149-151.	
108	TSIMIKAS et al. (2001) "Measuring Circulating Oxidized Low-Density Lipoprotein to Evaluate Coronary Risk." <i>Circulation</i> 103:1930-1932	
109	VAN LENTEN et al. (2001) <i>Circulation</i> 103:2283-2288.	
110	VENKATACHALAPATHI et al. (1993) "Effect of End Group Blockage on the Properties of a Class A Amphipathic Helical Peptide." <i>Proteins: Structure, Function, and Genetics</i> 15:349-359.	
111	WILSON et al. (1988) "High Density Lipoprotein Cholesterol and mortality: The Framingham Heart Study." <i>Arteriosclerosis</i> 8: 737-741	

Examiner Signature	Jeffrey E. Russel	Date Considered	April 17, 2005
--------------------	-------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

NOV 14 2003
OIP E SCIBS
PATENT & TRADEMARK OFFICE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/P

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/649,378
Filing Date	August 25, 2003
First Named Inventor	Alan M. Fogelman
Group Art Unit	1614
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-911250US
Date Submitted	May 27, 2004

U.S. PATENT DOCUMENTS

Class / Subclass

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
JBL	1	6,664,230		Fogelman et al.	12/16/2003	514/13
JBL	2	5,344,822		Levine et al.	9/6/1994	514/13

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T

Examiner
Signature

Jeffrey E. Russel

Date
Considered

April 17, 2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.